Cabometyx® in Combination with Nivolumab Shows Durable Survival Benefits At Over Three-years’ Follow-up in First-line Advanced Renal Cell Carcinoma

Prensa/medios de comunicación

Período14 feb. 2023

Cobertura de los medios

2

Cobertura de los medios